about the uSc School of pharmacy
One of the top 10 pharmacy schools nationwide and the highest ranked private school, the USC School of Pharmacy continues its century-old reputation for innovative programming, practice and collaboration. The School created the nation's first Doctor of Pharmacy program, the first clinical pharmacy program, the first clinical clerkships, the first doctorates in Pharmaceutical Economics and Regulatory Science, and the first PharmD/MBA dual-degree program, among other innovations in education, research and practice. The USC School of Pharmacy is the only private pharmacy school on a major health sciences campus, which facilitates partnership with other health professionals as well as new breakthroughs in care. It also is the only school of pharmacy that owns and operates three pharmacies.
The School is home to the International Center for Regulatory Science at USC, and is a partner in the Leonard D. Schaeffer Center for Health Policy and Economics and the USC Center for Drug Discovery and Development. The School pioneered a national model of clinical pharmacy care through work in safety-net clinics throughout Southern California. A focus on clinical pharmacy, community outreach, regulatory science, drug discovery and development, and health economics and policy positions the USC School of Pharmacy as a leader in the safe, efficient and optimal use of medication therapy that can save lives and improve the human condition.
in ThiS iSSue

Force of Nature
For more than a century, the USC School of Pharmacy has actively been an accelerant of change for the profession with the ultimate objective of improving health outcomes for people everywhere. Our cover story highlights just a few ways our faculty, students and alumni are increasing the velocity of the profession's impact.
It may seem unusual for the dean of the nation's top private pharmacy school to be shown racing across the cover of that school's magazine. Yet it seems an apt way to signal a new path forward-not just for the USC School of Pharmacy but, more importantly, for advancing the field of pharmacy itself.
We are entering a challenging but exciting new era in health care, one in which the pharmacist must play an increasingly vital and recognized role. The USC School of Pharmacy has long been not just a proponent of that shift in gear, but also an active force steering the profession toward greater influence and impact as a key driver of optimal health for patients everywhere. Thus, for the new name of our redesigned magazine, we chose to play on the word "results"-combining it with the familiar Rx. It has been proven time and again that engaging a pharmacist as an integral part of the health care team is a prescription for improved patient outcomes.
Our cover story demonstrates how the School continues to set the pace with groundbreaking research, innovations in clinical care and forward-looking educational advances that are accelerating the profession's impact on society. You'll learn more about how our faculty, students and alumni are blazing new trails in pharmacy-from the discovery of a new class of ovarian cancer drugs that may revolutionize treatment of that deadly disease to an interdisciplinary education model that is fueling a new approach for training tomorrow's health professionals.
In these pages, you will also read about the extraordinary career of Leonard Schaeffer, who recently committed $25 million to endow and support the Leonard D. Schaeffer Center for Health Policy and Economics, a collaboration between our School and the USC Price School of Public Policy. This leadership gift-the largest in our School's history-will strengthen the Schaeffer Center's continuing efforts to find answers to today's, and tomorrow's, most pressing health care challenges.
This net forward momentum is paving the road for what ultimately gives me the most hope of all-the quality and dedication of our students. Their passion will drive the future of our profession. There is no turning back.
R. Pete Vanderveen, PhD, RPh John Stauffer Decanal Chair in Pharmaceutical Sciences
The Road ahead
The School continues to set the pace with groundbreaking research, innovations in clinical care and forward-looking educational advances that are accelerating the profession's impact on society." >> letter From the deaN
We talk with Leonard D. Schaeffer about his incomparable career-from apprenticing with his pharmacist father to creating the Health Care Financing Administration to turning one of the nation's largest health insurance companies from near-bankruptcy into a $49 billion success story.
Cover story: force of Nature
In keeping with Newton's second law of motion-that acceleration is proportional to the force acting on it-the USC School of Pharmacy continues to help propel the profession forward.
global Reach
Explore the geography of the USC School of Pharmacy's international impact.
IN ThIS ISSUe
broad Spectrum
Read our latest news and notes, featuring the inaugural holder of the Quintiles Chair, recognition on the Pharmacy Today cover, major faculty honors, the largest gift in the School's history, and new educational offerings, from a residency in managed care and a dual degree in Global Medicine to Regulatory Science programs in the Bay Area. 
>> broad spectrum
The September 2012 issue of Pharmacy Today devoted its cover story to the USC Medication Therapy and Safety Initiative, which provides medication therapy management (MTM) and clinical services to the vulnerable in some of Los Angeles' most impoverished neighborhoods. The article profiles Steven Chen, PharmD, associate professor and Hygeia Centennial Chair in Clinical Pharmacy, who manages USC's clinical pharmacists as they provide vital care in safety-net clinics.
The School began working with safetynet clinics in 2002 under the direction of the late Kathleen Johnson, PharmD '78, MPH, PhD, vice dean of Clinical Affairs and Outcomes Sciences and chair of the Titus Family Department. Since launching the collaborations, the School has tracked and published the impact of clinical pharmacy services on health care quality, which shows substantial improvements in disease control, as well as cost containment, when a pharmacist is integrated into the health care team. The program currently covers 19 safety-net clinics and aims to be in 24 clinics over the next year.
The article pointed out how desperately the expansion is needed. With more than 2.7 million uninsured people living in Southern California, including an estimated 51,000 homeless, "physicians are overwhelmed as the demand for services has skyrocketed while the economy has plummeted," Chen says.
Paul Gregerson, MD, MBA, chief medical officer at JWHC Institute-one of the School's safety-net partners-is quoted as saying he has "witnessed the dramatic improvement in chronic disease and behavioral health outcomes that resulted after the USC Clinical Pharmacy Program was implemented." Gregerson adds that the USC School of Pharmacy is the "most valuable and rewarding community partnership we have."
Over the past eight years, with more than $15 million in grants to the School for the program, participating pharmacists have logged 45,000 individual MTM visits for patients with hypertension, diabetes, dyslipidemia, chronic heart failure, anticoagulation and other conditions. The program also provides ideal training for students and residents in caring for a diverse population and addressing a wide range of diseases and conditions, the article noted.
In addition to freeing up physicians to deliver more care and helping improve patient outcomes, the program demonstrates the cost savings that are achieved when pharmacists take a more direct part in care. The article highlighted data from two clinic partners, QueensCare Family Clinics and the Center for Community Health, showing that the pharmacist's role was associated with a 75 percent reduction in annual medication costs.
The benefits are incalculable-both to the people helped and to the advancement of the pharmacy profession itself through the data collected.
For more about the program, see the related story on page 26.
% reduction in annual medication costs associated with the pharmacist's role
Pharmacy Today covers mtm Initiative
SPRiNg 2013 5 busy San francisco-area professionals can now benefit from USC Regulatory Science courses in person without traveling to Southern California. the USC School of Pharmacy has begun offering core courses in mountain view, Calif., enabling bay Area residents to take master's degree and graduate certificate classes in this increasingly vital field.
"We are excited about expanding and partnering with bay Area pharmaceutical, biotech and medical device firms to bring new opportunities to students and professionals in Northern California," says frances Richmond, Phd, director of the Regulatory Science Program and the international Center for Regulatory Science at the USC School of Pharmacy. Richmond notes that USC Regulatory Science graduates are in great demand among top employers, as the biomedical industry's rapid growth has fueled a large demand for regulatory professionals, both nationally and internationally-a demand that, except through USC, remains largely unmet.
Courses at the mountain view location will be offered throughout the year. they include: introduction to medical Product Regulation-an overview of the profession that examines how agencies and companies interrelate-Regulation of drugs and medical devices, Quality Assurance, and Structure and management of Clinical trials, which focuses on real-life clinical situations and challenges. the latter includes a distance-learning module. Courses are offered on weekends to accommodate students' schedules.
the Regulatory Science program's extensive online offerings also are available to bay Area students, who will have the opportunity to create a hybrid education plan suited to their individual needs. in fact, the program now enables all students to "move back and forth seamlessly between distance courses and live courses at our locations in San francisco or los Angeles," says Richmond. Classes are open to those who have not yet been admitted to a formal program, and credit for all coursework will apply to the master's or certificate programs if students decide to pursue either option.
"
In The School of Pharmacy also houses the USC International Center for Regulatory Science, which will interface with Lakdawalla in his new role.
Lakdawalla's research focuses on understanding the long-term consequences of health policy and regulation for medical innovation and for future generations of patients. His work has investigated intellectual property and marketing in the pharmaceutical industry, regulatory exclusivity for drug makers, the design of incentives for medical innovation, the long-term impact of pharmaceutical price regulation, and the appropriate role of physician and drug-maker liability in the health care system.
He "We are in a time of unprecedented change in our health care system," says Hill-Besinque, assistant dean for Curriculum and Assessment and director of Experiential Programs at the USC School of Pharmacy. "CPhA is in a leadership and advocacy position to ensure that pharmacists and pharmacy services are enhanced as a result of these changes."
An expert on women's health, Hill-Besinque is a frequent media voice concerning emergency contraception and is also a specialist in menopause therapies. Other professional organizations for which she has served as a board member include the California Society of Health-System Pharmacists, the Southern California Society of Health-System Pharmacists and the Association of Reproductive Health Professionals.
Other faculty members holding leadership positions within CPhA are Melissa Durham, who chairs CPhA's Academy of Pharmacy Educators, and Jeffery Goad, a board trustee for the Academy of Pharmacy Educators.
the USC School of Pharmacy's new post-graduate residency program in managed care educates at the nexus of health care and the economy. the program trains students to ensure that patients achieve optimal health outcomes in a cost-effective manner by working in a range of areas, including formulary development, pharmacy benefit design, disease state management, patient and provider education, outcomes research and medication therapy management.
vickie Pon, the program's first resident, saw the USC managed care residency as a perfect fit for her post-graduate interests. "i decided to pursue a career in managed care because i wanted to be able to contribute positively to the most population groups," says Pon, who received her Pharmd at University of California, San francisco, after earning her undergraduate degree at the California institute of technology. "USC's academic program, combined with the unique range of experiences afforded at Caremore, offered the best learning opportunity," she says. "USC also provides great mentors, which i realized as soon as i interviewed here."
At Caremore, Pon works with patients, performing medication therapy management, as well as interfacing with nurses and physicians. "i see myself staying with Caremore and working in managed care after completing my residency," she says. "i hope to go on to a leadership track that integrates clinical pharmacy programs into various managed care models." " We are in a time of unprecedented change in our health care system." "leonard Schaeffer has demonstrated a lifelong commitment to relevant, evidence-based health policy research," says dana goldman, director of the Schaeffer Center and holder of the Norman topping Chair in medicine and Public Policy. "With this additional gift, he ensures that our mission of providing independent, innovative solutions to today's health policy challenges will endure beyond the current era of health care reform." established in 2009 with a gift from Schaeffer and his wife, Pamela, the Schaeffer Center is jointly housed at the USC School of Pharmacy and the USC Price School of Public Policy. it has rapidly developed into one of the nation's premier policy institutions, with more than $45 million in external research funding, including research grants from the National institutes of health and the Centers for medicare and medicaid Services (CmS).
"the center is an integral part of the work at the USC School of Pharmacy, with research to identify best practices for medication therapy that efficiently produces optimal health outcomes," says dean R. Pete vanderveen.
Research from the Schaeffer Center provides critical policy guidance and inventive solutions with the potential to transform health care systems. Research results-including novel analyses of preventive care, insurance competition, the fiscal future of Social Security and medicare, co-payments and prescription drug adherence, and which medical specialties are most likely to face malpractice claims-are routinely published in top peer-reviewed journals and featured in leading media outlets, such as The Wall Street Journal, The New York Times, Politico and NPR. Schaeffer Center faculty " As health care assumes an increasingly prominent place in public policy discussions, the USC Schaeffer Center will play an even more central role, while offering a uniquely interdisciplinary perspective." Goad is a strong advocate for the role of pharmacists as immunization providers and has developed training programs to promote this function. He was instrumental in establishing USC's community pharmacy residency program, which works to identify gaps in health care and use pharmacists to fill those needs. He also directs the USC International Travel Health Clinic, which provides health services to those in the USC community planning trips abroad. To expand this function nationally, Goad has partnered with Good Neighbor Pharmacy to train community pharmacists across the country to implement travel health services at their locations.
"Dr. Goad is the kind of leader who not only encourages his pharmacist colleagues and students to grow the role of community pharmacy by practicing at the highest level that our license allows, but he also furthers the profession through his work beyond the 'walls of pharmacy,' promoting the profession and our rightful place as the medication expert on the health care team," says Dean R. Pete Vanderveen. "Complementing our pharmacy curriculum with the global medicine program allows us to produce 21st century pharmacists with a unique global perspective," says Ronald Alkana, associate dean of graduate Affairs and interdisciplinary graduate Programs. the program examines the effects of disease, as well as the development of innovative solutions to address accompanying health and social issues to prevent global health crises.
Nassim lashkari, a third-year Pharmd student in the program, worked with a physician treating hiv-positive women and children in slum areas of india before coming to USC. She plans to return to this work with the added value of the Pharmd/mSgm. "my clinical work through the Pharmd program in the safety-net clinics of los Angeles has allowed me to work with vulnerable population groups, furthering my interest in and belief in the importance of cultural competency in garnering optimal health outcomes," says lashkari.
Increasing Global outreach
Goad honored by National association of chain drug stores from active research partnerships and major conferences, to student exchanges and service learning opportunities, the USC School of Pharmacy provides international leadership and maintains ties with other universities and institutions around the world. this map provides a quick snapshot of the School's global reach. Mexico: Students in USC's chapter of the Student National Pharmaceutical Association organize medical mission trips every three months to tijuana, mexico. the group also participates in service learning trips to remote villages in belize and Jamaica, providing health education and screenings.
PANAMA: tien Ng presented two talks at the Pan American heart failure Congress in Panama City in October 2012.
NortH AMericA: the USC School of Pharmacy maintains research and clinical relationships with scores of academic institutions, government agencies and industry partners throughout North America.
GHANA: the USC School of Pharmacy frequently hosts visiting international students, including recent delegations from China, ghana, macedonia, Spain, taiwan and turkey. "He ran an old-fashioned prescription pharmacy, making salves and filling capsules," recalls Schaeffer. "The doctors at Northwestern really liked it, because he could make up whatever they needed."
The elder Schaeffer-whose father was a doctormaintained an easy rapport with the physicians, who frequently consulted with him and depended on his expertise to customize medications for their patients. He also counseled customers, serving as an authority on both the pharmaceuticals prescribed to them and on questions relating to their health status. Many called him "Doc," remembers his son, who was often enlisted to make home deliveries.
"Both my parents were involved in helping peoplemy dad as a pharmacist and my mom as a social worker," says Schaeffer. "They did it on a one-to-one basis. I got it into my head that if you were in a position to influence public policy, you could have a positive impact on lots of people. I wanted to have a broader impact."
He enrolled at Princeton University, initially as a politics major-interning on Capitol Hill with Paul Douglas, the senior senator from Illinois and an influential mentor to Schaeffer-before switching to economics. "I realized that economics was probably a better basis for understanding public policy," he explains. "It was a circuitous route." After graduating in 1969, he returned to Chicago for a job with Arthur Andersen and worked on several political campaigns. "I learned a lot about politics, but decided I didn't want to be a politician. Getting elected is not the only way to influence public policy."
By age 27, he found himself doing just that, as deputy director of the Illinois Department of Mental Health. He soon was promoted to director of the Illinois Bureau of the Budget, where he earned a reputation for cost management. "It never occurred to me that combining the administration of these two federal programs without explicit approval might be flouting legislative intent," he recalls.
He just knew what had to be done, so he did it. When Harvard's Kennedy School of Government did a case study on his success in both government and in business, it was Schaeffer's chutzpah in merging Medicare and Medicaid that the students and faculty found most fascinating.
In the mid-1980s, he was recruited as president and CEO of Blue Cross of California-predecessor of WellPoint Health Networks-and was again charged with a massive restructuring when the company was on the brink of bankruptcy. He turned it around and grew the company's value from $11 million to $49 billion, changing its orientation from indemnity-based health insurance to managed care services.
Also during this period came Schaeffer's proudest achievement-creating a process for converting nonprofits into for-profit stockholder-owned entities and then giving stock to newly created foundations. "We ended up giving about $6.2 billion to charity," he says. "I don't think any other corporation has done that."
Although his work has evolved dramatically since those early days in his father's pharmacy, he says the apprentice pharmacist's license has proven helpful throughout his career. "As I got more and more significant jobs in health care, having that pharmacy license and experience allowed me to say to health care professionals, 'I've had some experience with patients,'" recalls Schaeffer. It demonstrated some understanding of the challenges faced by providers, and opened the door to discussing potential changes from the vantage point of mutual respect.
With both public and private experience and success to his credit, Schaeffer naturally has strong views on today's health care environment.
"Health care systems are not about health care," he says. "They are about social values." Schaeffer compares our American perspective with that of the UK, where it is "vitally important that everyone be treated 'equally' and that health care is free at the point of service. In the U.S., we've decided that health care belongs in the marketplace." He adds that, while Medicare was controversial when it was first established, it is now ingrained in our system, and that the American value structure also supports caring for the poor and disabled. "Everybody else in between … it's up to them. It goes to the heart of American democracy because we're all about individual rights." He adds that "the problem with the cost of health care is every cost is somebody's income and somebody else's treatment."
So how would he improve the system? He suggests that we: >> Shift the focus of prevention and wellness away from the health care delivery system. "Forty percent of ill health is a function of lifestyle. We need to start earlier, in schools, pharmacies and homes."
>> Pay for results, not for units of service. "We need to provide patients with evidence-based care and reimburse for good outcomes."
>> Change how we pay for care-paying for population health, not for individual services.
>> Empower patients to control how they die. "The last year of life is the most expensive in health care spending, typically resulting in poorer outcomes and poor quality of life."
By endowing the Leonard D. Schaeffer Center for Health Policy and Economics at USC-a collaboration between the School of Pharmacy and the Price School of Public Policy-he sees an opportunity to influence health and economic policy through meaningful, independent research. "You' d be stunned at how little evidence there is in health care policy decisions," he notes.
Schaeffer adds that, "If you look at the health care system, it's the only part of our economy where the most highly trained and most expensive technical person [the physician] is at the base of the pyramid."
He sees this as an opportunity for pharmacists, nurses and physician assistants to both triage and treat, with physicians focusing on those who need a physician's expertise. In many ways, this approach to health care comes full circle, harkening back to the days when Schaeffer's pharmacist father was trusted by both patients and physicians for his medication expertise and his counsel on health issues.
"Every other part of our economy is organized in this way," he says. "It's today's health care that's backwards."
Regarding the Affordable Care Act, Schaeffer cautions that the decade-long implementation period for the complicated legislation will likely be mired in small section repeals and waivers, as well as difficulty with the large components that are left to the states. "The federal government, I believe mistakenly, delegated to the states the definition of what is an essential health benefit," he explains. "So you're going to have 50 different versions of that."
While he acknowledges that the bill is associated with many pilot projects to identify ways to improve the quality of and access to care while reducing spending, he says these results may not come fast enough. "It's a great time for impacting public policy, a great time for the Schaeffer Center and a great time for the pharmacy world. It's going to be a chaotic decade, but quite a ride."
Read about Schaeffer's $25 million gift to the USC Schaeffer Center on page 8. As a tennis player, Megan Yardley understands the importance of speed-but only when coordinated with strategy and precision in hitting the ball to its target. Yardley brings these same skills to her work on drug development. She has never shifted focus from her goal, although she did augment her course of study to achieve it.
Yardley originally entered the USC School of Pharmacy as a PhD candidate in Molecular Pharmacology and Toxicology. Once she was at USC, Associate Professor Daryl L. Davies encouraged her to enroll in the new Master's of Science in Management of Drug Development (MDD) offered through the School's Regulatory Science program. The 32-unit program trains scientists to find faster ways of getting new drugs from the research bench to the patients who need them, all while maintaining vital safety standards. "There's an urgent medical/business need for professionals adept at innovating this process," says Davies, who directs the MDD program.
"The MDD gives me the opportunity to learn about the drug development process from discovery to clinical practice," says Yardley, who admits she "didn't fully understand what Regulatory Science was" before coming to USC.
She now pursues both degrees with equal diligence and the knowledge that each informs the other. "Because it takes so long-up to 20 years-from initial discovery to availability to patients, bench scientists often don't focus on steps beyond the discovery phase, and this can create major issues down the line," Yardley observes.
"You figure someone else down the road will take care of that, and you focus on the actual discovery."
Yardley, however, is dedicated to both discovery and expedited delivery. On the discovery front, her work as part of Davies' lab team includes research on a drug to treat alcohol use disorders. Yardley has spent the past three years testing the drug's efficacy in animal models. "We use a variety of drinking models to test the drug's efficacy and employ numerous behavioral paradigms to assess its toxicity," she says of the process, which explores potential negative effects as well as positive ones.
They look at such questions as: Does it cause depression? Aggression? How does it reduce alcohol intake? Does it cross the blood-brain barrier?
Research on alcoholism, led by both Davies and Professor Ronald Alkana, was what helped attract Yardley to USC in the first place. "Alcoholism has affected me personally," she says, recalling her father's struggles for sobriety.
A native of Bangor, Maine, Yardley did her undergraduate work at Stonehill College in Massachusetts and internships at Boston College and the Boston Veterans Hospital before moving to the sunny climes of Los Angeles to attend USC.
In addition to enjoying Southern California weather, Yardley appreciates the networking opportunities being a Trojan brings. "It's amazing all the ties people in Los Angeles have to USC," she says.
Her current apartment is even next to a tennis court. "Others in the program also play. It's a good way to let off steam."-SlW Ovarian cancer frequently eludes diagnosis because its symptoms are vague and no standard screening test is available. In many patients, by the time of diagnosis the tumor has already metastasized. Mortality rates for the disease have not improved in four decades. Complicating matters is the resistance that ovarian cancer routinely builds up against the drugs currently used to treat it.
New hope may be on the horizon, thanks to pioneering work by PhD candidate Shili Xu in the laboratory of Nouri Neamati, PhD, professor of Pharmacology and Pharmaceutical Sciences. Early in vitro research on ovarian cancer cells, followed by studies in animal models, shows promise for a novel, more powerful and less toxic class of chemotherapy, called PACMA31.
The name refers to a class of compounds, propynoic acid carbamoyl methyl amides-abbreviated as PACMAthat was discovered by testing nearly 10,000 chemical compounds on cancer cells in Neamati's lab. The research team-which includes Nicos Petasis, PhD, a professor of Chemistry in the USC Dornsife College of Letters, Arts and Sciences-synthesized more than 80 newly designed compounds and found one of them, PACMA31, to be extremely toxic to ovarian cancer cells. They patented the new drug and reported the findings in September in the Proceedings of the National Academy of Sciences (PNAS) with Xu as lead author.
The PNAS study shows that PACMA31 inhibits Protein Disulfide Isomerase (PDI), a protein highly expressed in ovarian cancer.
"Cancer cells proliferate fast," Xu explains. "They have to synthesize a lot of proteins, and PDI is a key enzyme for maintaining structural integrity of newly synthesized proteins. Therefore, PDI is overexpressed in cancer cells. Inhibiting PDI results in cancer cell death." PACMA31 holds numerous advantages as a treatment. It can be taken orally and significantly accumulates in cancer cells, while having limited harmful side effects in normal tissues. It is also what is known as an "irreversible" drug-meaning that it permanently latches on to its target, PDI, and refuses to wear off until the protein is degraded. That irreversibility could translate into patients needing lower doses of drugs, says Xu.
Currently, two major types of drugs are used against ovarian cancer: paclitaxel, which hinders cancer cell division by inhibiting the disassembly of microtubules; and carboplatin, which binds to and causes crosslinking of DNA that results in cancer cell death.
Unfortunately, these treatments come with a serious drawback, in addition to their toxicity. "A majority of patients will eventually become drug-resistant to what's available today," says Xu. "That's why we need new drugs for ovarian cancers."
As PACMA31 employs a different strategy, it can bypass the resistance that patients' bodies build up against paclitaxel or cisplatin. "We are exploring combination studies in order to find synergy between our drug and first-line therapy for ovarian cancer," says Neamati.
The team is also looking at ways to modify the structure of the compound to make it more potent and more active, which could eventlually help lower the cost of cancer therapy as well, says Xu.
The drug even holds potential beyond treating ovarian cancer. "We have tried the compound on other cancer cells-breast, colon and lung-and it worked on all of them," he says.
Even though PACMA31 requires more study and clinical trials-and may be years away from the marketplace -it holds great potential and so far shows no significant side effects.
"It seems to preferentially target tumors," adds Xu. 
Right: Neamati's team takes advantage of USC' s Center for High Performance Computing & Communication to test thousands of compounds with potential for major breakthroughs in the treatment of cancer and other diseases.
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SPRiNg 2013 23 The complexities of 21st century health care demand interdisciplinary teamwork to accelerate optimal patient outcomes. In typical Trojan fashion, schools across the university are working together to provide USC students with the education and experiences needed to become experts in their own field and in collaborating with other specialists. One such program, the Interprofessional Geriatrics Curriculum, achieves that while also helping chronically ill senior citizens. Ask 91-year-old Filomena Flores and she will be happy to tell you what the program means to her. Flores welcomes her team of USC students to her home at Tres Lomas Garden, an affordable housing complex for the elderly located just north of downtown Los Angeles. Her visitors have come from seven different professional programs at USC: dentistry, medicine, occupational therapy, pharmacy, physician assistant, physical therapy and social work. A faculty mentor accompanies them. The meeting is the first in a series aimed at teaching students to work as a team as they examine the health issues facing Flores and identify ways to improve the quality of her care.
"Comprehensive geriatric care is best given by an interprofessional team," observes Jo Marie Reilly, MD, co-director of the Keck School of Medicine Primary Care and Community Medicine Program.
Brad Williams, PharmD, CGP, professor at the School of Pharmacy, adds, "It's also a great way to teach students how to function on an interprofessional team, and to understand the expertise from each discipline and how they inform each other."
Williams and Reilly are among the program's faculty mentors who guide students as they prepare to interact with patients and obtain the information necessary for creating a management plan that meets the multilayered, complex health needs of the elderly.
"This is really a great way to understand what other professions provide, giving me insights as I offer the pharmacy perspective," says pharmacy student Brian Chou.
Chou also serves as co-president of another interdisciplinary project at USC, the Student Run Clinic, along with Keck School of Medicine student Michael Toboni. Last December, Chou and Toboni were asked to present their work in a national webinar offered by the U.S. Health Resources and Services Administration-a testament to the growing interest in interdisciplinary teamwork as the best method of patient care.
"The pharmacy aspect pertaining to the patient is just one part of the big picture," says Chou. "Each team member is able to elicit certain information that pertains to their respective profession, which collectively reveals pertinent medical and occupational issues."
The Interprofessional Geriatrics Curriculum is one of many programs at USC supplying students with firsthand understanding of the importance of cross-disciplinary teamwork and the value each specialty brings to patient care. "Further, most accrediting organizations for the various schools are now requiring interdisciplinary learning as part of the curriculum," says Kathleen Hill-Besinque, PharmD, MSEd, assistant dean for Curriculum and Assessment and director of Experiential Programs at the School of Pharmacy.
As students complete their first session with Flores, she holds the hands of two team members. "I look forward to our next meeting," she says.-Kv
Go Trojan Team ''
Each team member is able to elicit certain information that pertains to their respective profession, which collectively reveals pertinent medical and occupational issues." -bRiAN ChOU
Left: Pharmacy student Brian Chou, physician assistant student Kyle Johnson and medical student Hannah Segal confer with Filomena Flores at her home in Tres Lomas Garden.
Military personnel who sustain traumatic eye injuries during combat face myriad challenges to saving their vision-from lack of immediate access to advanced medical facilities to the arid Middle East climate reducing the effectiveness of eye drops and other treatments.
For the past three years, Assistant Professor Andrew MacKay has been developing elastin-like polymers designed to change the therapeutic delivery mechanism, retaining treatment on the eye's surface for a longer period of time to stimulate lubrication and healing.
He and his colleagues, including co-investigator Sarah Hamm-Alvarez-executive vice dean and the Gavin S. Herbert Professor in Pharmaceutical Sciences-recently filed a full patent application and garnered a twoyear, $250,000 grant from the Department of Defense's Vision Research Program to move this work from in vitro to in vivo exploration. The award "supports the exploration of highly innovative, untested, high-risk/ high-gain concepts, theories, paradigms, and/or methods" that address vision injuries among service members.
"The primary goal is to develop a novel targeted protein-based drug and delivery system that can be administered once by injection following acute ocular trauma," explains MacKay. "This will provide sustained release of therapeutics to initiate wound healing, sustain tissue lubrication in an arid environment and prevent further damage to delicate ocular surface tissue during transport to state-ofthe-art medical facilities."
Another key component of the team's research includes investigation of nanoparticlebased drug delivery methods that would not require the therapeutic to be injected into the eye, but instead would allow it to be targeted for delivery through the bloodstream directly to the eye's surface, where it would then be activated for release.
"This platform technology and specific approach are applicable to other chronic and acute diseases of the eye that do not respond effectively to topical eye drop administration, due to the need for frequent administration and poor patient compliance," says MacKay.
These conditions include glaucoma, Sjögren's syndrome, severe scleritis, peripheral ulcerative keratitis and mycotic keratitis, which collectively affect more than 3 million Americans each year.-SlW
Eyeing the Finish Line
Having already shown that inhibiting the monoamine oxidase-A enzyme (MAO-A) slows the acceleration of prostate cancer, University Professor Jean C. Shih now wants to put the brakes on the disease once and for all.
Shih's research has a head start, as her lab was the first to successfully clone human MAO-A and MAO-B genes. That pioneering research is an important building block in the future development of new treatments for depression, aggression, anxiety and even autism.
"Since MAO-A inhibitors are already used to treat depression, we can expedite the testing of our hypothesis that these agents can also target prostate cancer cells," says Shih, who holds the Boyd P. and Elsie D. Welin Professorship in Pharmaceutical Sciences. The study includes using optical imaging to follow an infrared drug dye as it moves within tumors to monitor their growth. The U.S. Department of Defense saw the potential in this research and awarded her and co-investigator Bogdan Olenyuk, an assistant professor at the School, and colleagues from Cedars-Sinai Medical Center a three-year, $579,499 grant to support the investigation of exactly how MAO-A affects the progression of prostate cancer. The Defense Department made the award through its Prostate Cancer Research Program, which funds high-risk, high-impact research to speed up treatments for the disease. If Shih and Olenyuk are right, the impact will indeed be enormous in targeting treatment to prostate cancer cells. "Our goal is to translate research findings into the clinic," Shih says. "Ultimately, our aim is to reduce or eliminate the suffering and death attributed to prostate cancer."-SlW
Putting the Brakes on Prostate Cancer
The human MAO molecule was first modeled by University Professor Jean C. Shih and collaborators.
While transplantation offers new hope to patients suffering organ failure, careful medication compliance is essential to their long-term health following these life-saving procedures. Immunosuppressive therapy helps prevent rejection of replacement organs and tissues, as well as infection.
"The average number of medications a transplant patient receives is between 10 and 15, sometimes up to 20," says Raffi Svadjian, director of Transplant Pharmacy Services at the USC School of Pharmacy. "While a few of those may eventually come off their profile, they must remain on about 10 of those medications for the rest of their lives."
To help patients manage the challenges of sticking with such a regimen, and to help monitor any adverse reactions or lack of efficacy in a particular individual, the USC School of Pharmacy has partnered with Keck Hospital of USC to maintain a continuum of care from pre-transplantation through long-term medication management.
"Our pharmacy calls each patient once a month to check if they need refills, answer any questions and determine if they are having any difficulties," says Svadjian. "It helps us provide better customer service, increase compliance, alert transplantation coordinators and physicians of any potential medication issues, and improve patient outcomes."
The number of transplants performed in the U.S. each year continues to grow-from 24,239 in 2001 to 28,537 in 2011-according to the Organ Procurement and Transplantation Network of the U.S. Health Resources and Services Administration. USC's transplantation program is growing even more rapidly, increasing the need for long-term, coordinated medication management. In fiscal year 2012, USC surgeons performed 409 transplants, the largest number being 115 kidney transplants, followed by 79 liver transplants. In FY 2011, the total number of transplants was 320. USC also performs heart, lung and bone marrow transplantation.-SlW Eileen Goodis, PharmD '77, combined her passion and expertise in the pharmacy profession with an innate entrepreneurial acumen-she ran her first enterprise, a neighborhood day camp, at age 10-to launch a number of businesses. They have included an institutional pharmacy company, a home infusion service started in the 1980s and a medication therapy management company she established the following decade.
"Pharmacists have such unique abilities," she says. "No other health professional is trained to do what we do." After earning her Doctor of Pharmacy degree, she completed a residency in consultant pharmacy, also at the USC School of Pharmacy.
Goodis credits that residency program as a life-changing experience that influenced her career direction and fostered her interest in expanding the role of the pharmacist in order to optimize patient outcomes. "Anyone on three or more medications should have their own pharmacist," says Goodis. She saw that need firsthand through her work with geriatric patients, who were often on more than a dozen drugs-which led in many instances to life-threatening medication interaction problems. In 1974, Medicare instituted mandatory monthly drug regimen reviews by a pharmacist for nursing-home patients to address this persistent problem, which started the field of "consultant pharmacy." "I soon realized that all patients on multiple medications, regardless of age, need to have regular drug regimen reviews," says Goodis. New medication therapy management regulations may finally make this a reality.
With an eye toward advancing the profession's future, Goodis has consistently shared her knowledge with students, providing rotations and paid internships at her companies. Her mentorship has inspired scores of new pharmacists over the years. In addition to providing hands-on opportunities, Goodis also teaches an entrepreneurial course at the School.
She and her husband, Eric Strom, MD, remain ardent supporters of the School, most recently endowing a scholarship. (See article on Widney Society, page 28.) Goodis has also funded translational research in addition to connecting the School with foundations for research support.
"My education at the USC School of Pharmacy was my steppingstone to wonderful entrepreneurial opportunities," says Goodis. "I always tell students to not be afraid to step out. If you have an idea, think it through, write it up, present it to a mentor and test it out. You can accelerate your career and the profession, but you have to step out to do it."-Kv
Igniting Initiative Driving Transplant Success
Eric Strom, MD, and Eileen Goodis, PharmD '77 An initiative by The Science Coalition (TSC) highlights USC School of Pharmacy faculty members Roberta Diaz Brinton and Andrew MacKay as two of the leading scientists fueling the nation's innovation. The TSC campaign stresses how the crucial advances resulting from federally funded research pay dividends to society far beyond the initial investment.
In the video featuring Brinton-the R. Pete Vanderveen Chair in Therapeutic Discovery and Development-she discusses her efforts to better understand how Alzheimer's disease affects women, who account for 68 percent of those with the condition. Instead of following the assumption that more women develop Alzheimer's because they tend to live longer than men, Brinton explains, "Our research shows that it's really the way the female brain ages that puts them at risk."
Her discoveries have led to strategies for preventing the disease's development, including an alternative to estrogen therapy that stops the brain from "switching over to the Alzheimer's pathway" as it ages. This alternative carries the benefits of the therapy it replaces, without the risk factors to the breast or uterus.
McKay's video addresses his use of nanomedicine to find complements and alternatives to radiation and chemotherapy in cancer treatment. "Our lab uses cells to generate very precise polymers that are made up of peptides like other proteins in your body," he says, adding that the aim is to "build small devices that can operate inside the biological environment of the body."
The result will be better-customized drugs that contain "an imaging component that allows us to directly detect how these drugs are distributed within patients," says MacKay, an assistant professor at the School.
Brinton and MacKay are both conducting true bench-to-bedside research that, ultimately, will save lives. Alzheimer's disease is the sixth leading cause of death in the nation, and cancer is the second.
The videos are available at innovators. sciencecoalition.org and on YouTube.-SlW
Fueling America's Innovation
With more than a decade of service in safety-net clinics-and a commitment to expanding into a total of 24 such sites by the end of 2013-the USC School of Pharmacy has long been a leader in providing comprehensive clinical pharmacy care to those most in need. The School remains a vocal advocate for the impact such intervention plays in patient health as well as the resulting cost containment.
As testament to its leadership in this arena, the Center for Medicare and Medicaid Innovation awarded the School a $12 million grant to expand this work and to demonstrate and evaluate a model that uses pharmacists in primary care settings to cost effectively improve health outcomes and medication safety. Associate Professor Geoffrey Joyce is the co-principal investigator on the project, along with Martin Serota, MD, chief medical officer for AltaMed Health Services.
The Centers for Disease Control and Prevention (CDC) issued a report in August 2012 that underscored the growing recognition of the importance of having a pharmacist on the health care team. "Models of innovative care involving pharmacists can ultimately help alleviate demands on the health care system (e.g., access, safety, quality, cost, provider shortages, etc.) and improve patient outcomes." The CDC found a return on investment as high as 12:1, with an average rate of return between 3:1 and 5:1. "This value is based on the ability of medication management services to reduce hospital admissions, use of unnecessary or inappropriate medications, emergency room admissions and overall physician visits," the report noted.
USC's project targets high-risk patients with difficult-toachieve chronic disease control who receive individualized services from pharmacists. Patient outcomes are being measured against those of similar patients in other clinics not receiving pharmacist care, providing the data to demonstrate the program's impact.
"Our estimate of more than $40 million in return on investment is on the conservative side," says Steve Chen, the Hygeia Centennial Chair in Clinical Pharmacy at the School, who is a co-investigator overseeing the clinical aspects of the project. Although the effort focuses on the underserved, Chen adds, "the results of this project will be applicable to any health care setting across the board. This work will advance the care provided to all Americans."-SlW
Furthering Innovations in Care
Clinical pharmacist Michelle Lee and ambulatory care resident Tina Patel counsel a patient at a safety-net clinic.
Sometimes innovations come not through speed but through helping others tear down barriers in their own lives. PharmD candidate Amanda Wong is doing that and more in partnership with the Braille Institute in Los Angeles, where she provides counseling and workshops to help clients manage their medications and improve their health.
"Before my project, the Braille Institute participants were not aware of the many skills of pharmacists, such as providing screenings and vaccinations, or about the safety issues and risks that can occur with poor medication adherence," says Wong.
Last spring, Wong earned a U.S. Albert Schweitzer Fellowshipone of only 250 nationwide. The fellowship provides a stipend that allowed her to expand the project she had already piloted, providing support to train other students and develop educational seminars and a health fair for Braille Institute clients.
She and her fellow students also offer individualized counseling, with clients bringing in their medications, vitamins and supplements. "If you just use your sense of touch, it's easy to make a mistake," she notes. "Drug manufacturers change the shape and color of medications frequently. Touch should not be the only way patients have of distinguishing among their prescriptions."
With the support of preceptors Maria Kootsikas, Cecilia Wu, Tatyana Gurvich and Jacqueline Jacobson-all alumnae of the School-and faculty advisers Bradley Williams and Steven Chen, the budding pharmacists check for potential interactions and other hazards. They also help clients organize their medications, develop strategies for identifying which pill is which and distribute Braille pillboxes to clients who need them.
"When patients do not take their medicine as directed, it can greatly affect their health," Wong adds. "But many patients don't want to take medications just because their caregiver says they are supposed to. They want increased independence." She is helping the blind and visually impaired achieve just that. This work has long been important to Wong. She spent many hours volunteering at the Braille Institute in Orange County while in high school.
"Now that I'm in pharmacy school, I wanted to help this patient population even more, with the goal of improving medication adherence and health outcomes," she says. "It's important even for those who are not visually impaired, because eyesight tends to worsen as people age."-SlW
Breaking Through Barriers
Pharmacy student Amanda Wong reviews medications with Trina Champe at the Braille Institute in Los Angeles.
>> GIvING
When USC held the inaugural event in November for the Widney Society, honoring those who have donated a million dollars or more to the university, the School of Pharmacy was well represented. The program featured a special performance by Gladys Knight and a theme celebrating the five attributes of the ideal Trojan as inscribed on the Trojan Shrine: "faithful, scholarly, skillful, courageous and ambitious."
Those qualities remain as essential now as when a pharmacist-former California Governor John G. Downey-joined fellow philanthropists and community leaders Orzo W. Childs and Isaias W. Hellman in helping Judge Robert Maclay Widney found USC 132 years ago.
Fittingly, the gala took place outside Widney Alumni House, the university's first-ever building. A highlight of the evening was the unveiling of a commemorative book that will contain the signatures of all Widney Society members. The book will be kept in the archives of Doheny Memorial Library, and new members will have the opportunity to add their signatures at special events in the years ahead.
"When USC was founded in 1880, the university had great ambitions but only modest financial resources," says USC President C. L. Max Nikias. "Many of our competitors had tremendous advantages of land or money. It was USC's chief founder, Robert Maclay Widney, who inspired the very first donations to this university's endowment-he raised $100,000 in 1880. Named after USC's visionary founder, this society will honor the visionaries of our day and time."
At the School of Pharmacy, the extraordinary support of Widney Society members has created professorships that help attract and retain leaders in the field to our faculty, provided scholarships and community projects that benefit students and the public, enhanced infrastructure, and established funding for breakthrough research and to inform policy.
The inaugural members of the Widney Society from the School of Pharmacy are listed opposite with just a sample of the projects they have so generously supported. These highlights of each member's giving are by no means a complete list of their visionary leadership, which has allowed the School to remain an accelerating force in health care. A charitable remainder trust (CRt) offers donors a way to make a meaningful gift to the USC School of Pharmacy in the future, while simultaneously providing a source of income for life and an immediate tax deduction.
A CRt is a separate legal entity administered by a trustee. the donor, USC, a financial adviser or an institution can serve as trustee. if USC is named as the trustee and remainder beneficiary, the university can provide tax benefit analyses and prepare the trust documents to establish a CRt at no cost to the donor. in addition, USC can administer the trust and manage trust assets without charging a fee. USC is currently the trustee for more than 200 CRts and manages more than $145 million in CRt assets.
A CRt pays individual beneficiaries an annual amount for the rest of their lives or a fixed term of up to 20 years. life-income beneficiaries can be the donor, family members or others. gift taxes may be applicable if the donor does not designate him/ herself and/or a spouse as the beneficiary.
donors who create a CRt can claim an immediate income tax deduction that represents the present value of the future gift to USC. the trust principal is normally invested for total return, and its growth is tax-free. it can be invested in a variety of diversified portfolios, including USC's endowment. however, the distributions paid to the beneficiary are taxable.
When the CRt ends, its remaining assets are distributed to USC for the purpose designated by the donor.
A CRt can be funded with cash or appreciated property. While the mechanics of the CRt and payout received will not change as a result of the assets used to fund the CRt, gifts of appreciated securities or property may provide substantial tax benefits to the donor in the form of avoidance of capital gains taxes. because a CRt is exempt from federal income taxes, donors are able to completely bypass the capital gains tax upon the sale of the appreciated property if such property is transferred to the CRt. "i was translating what the french doctors were telling them, across the ocean," recalls bonnet, who earned his mS in Pharmaceutical economics and was a student of dr. Johnson's. "i quickly realized how severe Kathy's injury was and decided i had to go to france to help." his partner was supportive of his decision, and Patrick soon boarded a plane to france, leaving his two small children at home in milwaukee, where he works in the health economics group for ge healthcare.
"Kathy was my mentor at USC and had always been there for me," says bonnet. "i owe her a lot. it was my turn to be there for her." bonnet was with dr. Johnson, her husband, Wynnsan moore, and their two children, Kimberly and Alex, during the many procedures performed to try to save her life. Unfortunately, her injuries proved to be too severe. in the aftermath of that devastating news, bonnet was indispensable in making arrangements to bring dr. Johnson home, helping with the paperwork at the consulate.
flying home, he reflected on the trojan family, its strength and wonderful bond, and the legacy left by his mentor, who inspired so many future professionals.
"Kathy always had time to talk and to listen," he adds. "She had 100 ideas a minute and always a little laugh to share. i will miss her." in MeMoriaM roscoe Atkinson, MD-a part-time faculty member of the USC School of Pharmacy for the past 15 years and longtime professor at the Keck School of Medicine of USC-died in August at the age of 53. Recognized by his peers and beloved by his students for his passion for and excellence in teaching, Dr. Atkinson garnered teaching awards for 10 consecutive years. He was especially known for using humor and innovative video technology, rock music and electronic media for making his lectures dynamic and memorable.
TranSlaTing coMpaSSion
Darren charles Abbott, 51, a pharmacy technician at the School's Plaza Pharmacy, died on December 29. A dedicated member of the pharmacy team since 2006, he was known for his kind and collegial attitude.
FaculTy updaTeS
36 esults >> USC SChOOl Of PhARmACy glen Stimmel serves as project lead for a College of Psychiatric and Neurologic Pharmacists foundation (CPNPf) effort to connect psychiatric pharmacists with community pharmacists to enhance the care for those living with mental illness.
to launch the project, a survey was conducted by CPNPf and the National Alliance on mental illness. it found that approximately 75 percent of individuals living with mental illness and their caregivers seldom or never receive safety or effectiveness monitoring assistance from community pharmacists. lack of private space to discuss medication issues was cited as the greatest obstacle.
Although 91 percent are very comfortable going to community pharmacists and 83 percent feel respected by their pharmacist, according to the survey, 43 percent nonetheless feel that they do not have a strong professional relationship with their pharmacist. And most receive their prescription at the cash register with minimal or no interaction with their pharmacist.
With only a couple of thousand pharmacists in the country specializing in psychiatric medications, partnership with community pharmacists will be essential to effectively caring for the millions who are taking prescriptions for psychiatric disorders.
Phase two of the project will involve analysis of the survey results along with development of strategies to link psychiatric pharmacists and community pharmacists to improve the level of support provided to patients.
connecting with community pharmacists
Associate Professor Neeraj Sood has been awarded a $927,059 grant from the National Institutes of Health (NIH) to investigate the long-term effects of consumer-directed health plans. Sood, who also serves as director of international programs at the USC Leonard D. Schaeffer Center for Health Policy and Economics, will examine how these plans influence patients as they shop for preventive services.
In exchange for lower premiums, consumer-directed health plans feature higher deductibles for certain services. They shift incentives, motivating patients to approach health care services as cost-conscious shoppers. For example, while these plans may offer complete coverage for such primary preventive services as cancer screenings and cholesterol testing, they also require patients to fully cover secondary preventive measures, including medications for diabetes, until the deductible is met.
"As far as we know, this project would be the first to comprehensively estimate the long-term effects of consumer-directed health plans on the use of preventive services," says Sood.
Findings from this project will provide vital data to policymakers and insurers as they design new plans to keep costs down while optimizing health outcomes. 108 % increase
